Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Aura Biosciences (NASDAQ: AURA) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. CEO Elisabet de los Pinos will engage in a fireside chat on December 3, 2024, at 2:35 p.m. ET. The clinical-stage biotechnology company, which focuses on developing precision therapies for solid tumors, will make the presentation available via live webcast on their investor relations website. A replay will be accessible for 90 days after the event.
Aura Biosciences (NASDAQ: AURA) ha annunciato la sua partecipazione alla 7ª Conferenza Annuale Evercore ISI HealthCONx. L'amministratore delegato Elisabet de los Pinos parteciperà a un'intervista informale il 3 dicembre 2024, alle 14:35 ET. L'azienda biotecnologica in fase clinica, che si concentra sullo sviluppo di terapie di precisione per i tumori solidi, renderà disponibile la presentazione tramite webcasting live sul suo sito web per le relazioni con gli investitori. Una registrazione sarà accessibile per 90 giorni dopo l'evento.
Aura Biosciences (NASDAQ: AURA) ha anunciado su participación en la 7ª Conferencia Anual Evercore ISI HealthCONx. La CEO Elisabet de los Pinos participará en una charla informal el 3 de diciembre de 2024, a las 2:35 p.m. ET. La empresa de biotecnología en etapa clínica, que se centra en el desarrollo de terapias de precisión para tumores sólidos, hará la presentación disponible a través de una transmisión en vivo en su sitio web de relaciones con los inversionistas. Una repetición estará accesible durante 90 días después del evento.
Aura Biosciences (NASDAQ: AURA)는 제7회 Evercore ISI HealthCONx 컨퍼런스에 참여한다고 발표했습니다. CEO 엘리자벳 데 로스 피노스는 2024년 12월 3일 오후 2시 35분 ET에 대담에 참여할 예정입니다. 고형 종양에 대한 정밀 치료 개발에 중점을 둔 임상 단계의 생명공학 회사인 이곳은 투자자 관계 웹사이트를 통해 실시간 웹캐스트로 발표를 제공할 것입니다. 이벤트가 끝난 후 90일 동안 다시 볼 수 있습니다.
Aura Biosciences (NASDAQ: AURA) a annoncé sa participation à la 7ème Conférence Annuelle Evercore ISI HealthCONx. La PDG Elisabet de los Pinos participera à une discussion le 3 décembre 2024 à 14h35 ET. Cette entreprise de biotechnologie en phase clinique, axée sur le développement de thérapies de précision pour les tumeurs solides, rendra la présentation disponible par le biais d'une diffusion en direct sur son site Web dédié aux relations avec les investisseurs. Un replay sera accessible pendant 90 jours après l'événement.
Aura Biosciences (NASDAQ: AURA) hat seine Teilnahme an der 7. jährlichen Evercore ISI HealthCONx-Konferenz bekannt gegeben. CEO Elisabet de los Pinos wird am 3. Dezember 2024 um 14:35 Uhr ET an einem Gespräch teilnehmen. Das biopharmazeutische Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Präzisionstherapien für solide Tumore konzentriert, wird die Präsentation über einen Live-Stream auf seiner Website für Investorenbeziehungen zur Verfügung stellen. Eine Wiederholung wird 90 Tage nach der Veranstaltung zugänglich sein.
- None.
- None.
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 2:35 p.m. ET.
The live webcast of the fireside chat will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.
For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.
Investor Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com
Media Contact:
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744
FAQ
When is Aura Biosciences (AURA) presenting at the Evercore ISI HealthCONx Conference 2024?
How long will the replay of Aura Biosciences' (AURA) Evercore conference presentation be available?
What type of therapies is Aura Biosciences (AURA) developing?
Where can I watch Aura Biosciences' (AURA) Evercore conference presentation?
